Esomeprazole Sodium Patent Expiration

Esomeprazole Sodium is Used for short-term treatment of gastroesophageal reflux disease (GERD) when oral therapy with Nexium capsules is not possible or appropriate. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Nexium Iv on Mar 31, 2005. 8 different companies have introduced drugs containing Esomeprazole Sodium.


Esomeprazole Sodium Patents

Given below is the list of patents protecting Esomeprazole Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Nexium Iv US5877192 Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole May 27, 2014

(Expired)

Astrazeneca
Nexium Iv US5877192

(Pediatric)

Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole Nov 27, 2014

(Expired)

Astrazeneca
Nexium Iv US6143771 Compounds May 27, 2014

(Expired)

Astrazeneca



Esomeprazole Sodium Generics

Several generic applications have been filed for Esomeprazole Sodium. The first generic version for Esomeprazole Sodium was by Sun Pharmaceutical Industries Ltd and was approved on Mar 18, 2013. And the latest generic version is by Hainan Poly Pharm Co Ltd and was approved on Feb 10, 2022.

Given below is the list of companies who have filed for Esomeprazole Sodium generic.


1. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 1 generic for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 40MG BASE/VIAL injectable Discontinued INTRAVENOUS N/A Sep 25, 2015


2. DEVA HOLDING AS

Deva Holding As has filed for 1 generic for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Deva Holding As.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 40MG BASE/VIAL injectable Prescription INTRAVENOUS AP Mar 6, 2017


3. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 2 different strengths of generic version for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 40MG BASE/VIAL injectable Prescription INTRAVENOUS AP Aug 10, 2016
EQ 20MG BASE/VIAL injectable Discontinued INTRAVENOUS N/A Aug 10, 2016


4. GLAND PHARMA LTD

Gland Pharma Ltd has filed for 2 different strengths of generic version for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE/VIAL

(reference standard)

injectable Prescription INTRAVENOUS N/A Apr 1, 2020
EQ 40MG BASE/VIAL injectable Prescription INTRAVENOUS AP Apr 1, 2020


5. HAINAN POLY

Hainan Poly Pharm Co Ltd has filed for 1 generic for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Hainan Poly.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 40MG BASE/VIAL injectable Prescription INTRAVENOUS AP Feb 10, 2022


6. MYLAN

Mylan Laboratories Ltd A Viatris Co has filed for 2 different strengths of generic version for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE/VIAL injectable Discontinued INTRAVENOUS N/A May 17, 2017
EQ 40MG BASE/VIAL injectable Discontinued INTRAVENOUS N/A May 17, 2017


7. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Esomeprazole Sodium. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE/VIAL injectable Discontinued INTRAVENOUS N/A Mar 18, 2013
EQ 40MG BASE/VIAL injectable Discontinued INTRAVENOUS N/A Mar 18, 2013